10-K: Fate Therapeutics Advances Cell Therapies, Reports Reduced Losses

Fate Therapeutics, a clinical-stage biopharmaceutical company, reported reduced net losses in 2025 while advancing its iPSC-derived cellular immunotherapy pipeline for autoimmune diseases and cancer.

Summary

• Fate Therapeutics is a clinical-stage biopharmaceutical company developing off-the-shelf, multiplexed-engineered T-cell and NK cell immunotherapies from induced pluripotent stem cells (iPSCs) for autoimmune diseases and cancer.
• The company reported a net loss of $136.3 million for the year ended December 31, 2025, an improvement from a net loss of $186.3 million in 2024.
• Cash, cash equivalents, and investments totaled $205.1 million as of December 31, 2025.
• Research and development expenses decreased to $107.8 million in 2025 from $135.0 million in 2024, primarily due to lower employee stock-based compensation, depreciation, and third-party consultant expenses.
• General and administrative expenses decreased to $46.5 million in 2025 from $74.2 million in 2024, mainly due to reduced patent and legal expenses and employee stock-based compensation.
• FT819, a CD19-targeted CAR T-cell candidate for moderate-to-severe Systemic Lupus Erythematosus (SLE), received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA in April 2025.
• Preliminary Phase 1 data for FT819 in SLE patients showed progressive decreases in SLEDAI-2K scores and rapid, deep B-cell depletion, with two lupus nephritis patients achieving complete renal response.
• The company expanded the FT819 Phase 1 trial to include additional B cell-mediated autoimmune diseases: anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV), idiopathic inflammatory myositis (IIM), and systemic sclerosis (SSc).
• FT836, a MICA/B-targeted CAR T-cell candidate for solid tumors, received IND allowance in July 2025, with Phase 1 clinical investigation initiated in November 2025 without conditioning chemotherapy.
• FT522, a CD19-targeted CAR NK cell candidate, completed its Phase 1 trial in relapsed/refractory B-cell lymphoma and received IND allowance in October 2024 for B cell-mediated autoimmune diseases.
• The collaboration with Ono Pharmaceutical for solid tumor candidates (FT825, Candidate 3) continues, with committed funding through June 2026 and potential future milestones up to $843.0 million.
• The company implemented a corporate restructuring in August 2025, reducing its workforce by approximately 12% to streamline operations and extend cash runway.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive update. While the company continues to incur losses and faces significant funding needs, the reduced net loss, successful cost management, and positive clinical and regulatory advancements for its pipeline candidates, particularly the RMAT designation for FT819 and the initiation of conditioning-free trials, demonstrate strong operational progress and de-risking of its novel platform.

Positives

• Net loss decreased to $136.3 million in 2025 from $186.3 million in 2024, indicating improved financial performance.
• FT819 received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA in April 2025 for moderate-to-severe SLE, which may expedite development and review.
• Preliminary Phase 1 data for FT819 in SLE showed promising activity, including progressive decreases in SLEDAI-2K scores and rapid B-cell depletion, with a favorable safety profile (no DLTs, ICANS, GvHD, low CRS).
• Two lupus nephritis patients treated with FT819 achieved complete renal response (CRR) at 2 and 6 months, respectively.
• The FT819 clinical trial expanded to include additional B cell-mediated autoimmune diseases (AAV, IIM, SSc), broadening the potential market.
• FT836, a novel CAR T-cell for solid tumors, received IND allowance in July 2025 and initiated Phase 1 clinical investigation in November 2025, notably without conditioning chemotherapy.
• Preclinical data for FT836 demonstrated potent and durable CAR-dependent antigen-driven proliferation across diverse solid tumors and potential for combination with Paclitaxel chemotherapy.
• FT522, a CAR NK cell candidate, completed its Phase 1 trial in B-cell lymphoma and received IND allowance for B cell-mediated autoimmune diseases, showing persistence without conditioning chemotherapy in preclinical studies.
• The collaboration with Ono Pharmaceutical continues to provide committed funding for research and preclinical development through June 2026, with potential for significant future milestone payments and royalties.
• The company maintains a strong intellectual property portfolio with over 600 issued patents and 550 pending applications.

Negatives

• The company continues to incur significant net losses, with an accumulated deficit of $1.5 billion as of December 31, 2025.
• Collaboration revenue decreased to $6.6 million in 2025 from $13.6 million in 2024, primarily due to the achievement of a clinical development milestone in 2024 that did not recur.
• Cash, cash equivalents, and investments decreased to $205.1 million as of December 31, 2025, from $280.1 million as of December 31, 2024.
• The company implemented a corporate restructuring in August 2025, including a 12% workforce reduction, indicating ongoing efforts to manage expenses amidst financial challenges.
• The company is subject to multiple ongoing securities class action and derivative lawsuits related to alleged false/misleading statements and the termination of the Janssen Agreement.
• The stock price appreciation milestones liability under the Amended MSKCC License decreased, which could imply a lower stock price or re-evaluation of the likelihood of reaching higher thresholds.
• The company has limited experience in commercializing therapeutic products and will need to develop significant marketing and sales capabilities if products are approved.

Risks

• Product candidates may fail to demonstrate safety, potency, durability, and efficacy, or may cause undesirable side effects, delaying or halting development or preventing regulatory approval.
• Development of product candidates requires substantial additional funding, which, if available, may cause dilution to stockholders, and without which preclinical or clinical development cannot be completed.
• The regulatory approval process for novel product candidates is particularly uncertain, and product candidates could fail to receive regulatory approval for many reasons, including disagreements with regulatory authorities on study design, data interpretation, or manufacturing comparability.
• The company may elect to deprioritize or discontinue clinical development of one or more product candidates due to prioritization, clinical data, or competitive landscape.
• Inability to use iPSC technology and gene-editing technology in product creation would significantly harm the business.
• Delays in initiating, conducting, or completing clinical trials due to difficulties recruiting investigators, enrolling patients, or manufacturing adequate clinical supplies.
• Significant competition in an environment of rapid technological change from other biotechnology and pharmaceutical companies.
• Initial, interim, and preliminary data from preclinical studies or clinical trials may change as more data becomes available and are subject to audit and verification.
• Manufacture and distribution of product candidates is complex and subject to risks, including additional FDA or foreign regulatory requirements, which could limit supply and increase costs.
• Limited experience manufacturing on a clinical scale and no experience on a commercial scale, with potential failures leading to delays or impaired commercialization.
• Dependence on third-party suppliers, including sole source suppliers, for certain equipment and components, with loss of suppliers adversely impacting clinical trials.
• Challenges recruiting and retaining key personnel due to labor market changes and competition.
• Cost fluctuations and inflationary pressures, including increases in prices of materials and labor, may adversely impact operating performance and cash utilization.
• Dependence on strategic partnerships and collaboration arrangements, which if unsuccessful or terminated, could result in delays and obstacles.
• Limited operating history and anticipated continued significant losses for the foreseeable future.
• Inability to protect intellectual property or obtain and maintain patent protection, allowing competitors to develop similar products.
• Failure to comply with obligations under intellectual property license agreements could lead to loss of rights.
• Inability to obtain or maintain necessary rights to product components and processes, leading to more costly or adverse operations.
• Regulatory approval failure from FDA or comparable foreign authorities would prevent or delay commercialization.
• Lack of experience in marketing, sales force, or distribution capabilities could hinder successful commercialization.
• Commercial success depends on market acceptance by physicians, patients, and third-party payers, which may require additional evidence.
• Security breaches, loss of data, and other disruptions could compromise sensitive information and impact operations.
• Principal stockholders and management own a significant percentage of stock, potentially exercising significant control.
• Stock price is subject to fluctuation based on various factors.
• Qualifying as a smaller reporting company and non-accelerated filer, and complying with reduced reporting requirements, could make stock less attractive.
• Global economic and market conditions, public health emergencies, geopolitical tensions, or regulatory developments could adversely impact business.
• Potential product liability exposure far in excess of limited insurance coverage.
• Employees or third-party service providers may engage in misconduct or improper activities, including noncompliance with regulatory standards and insider trading.
• Risks related to the privacy of personal information and compliance with data protection laws (e.g., HIPAA, CCPA, GDPR).
• Increasing use of artificial intelligence-based software may result in reputational harm or liability.
• Adverse developments affecting the financial services industry (e.g., bank failures) could affect liquidity and financial condition.
• Earthquakes, wildfires, power outages, or other natural disasters could disrupt operations.
• Failure to maintain an effective system of disclosure controls and procedures and internal controls.
• Failure to comply with environmental, health, and safety laws and regulations.
• Changes in tax law may adversely affect the company or investors.

Future Outlook

The company anticipates continued significant losses for the foreseeable future as it advances its clinical and preclinical development programs. It expects to require substantial additional funding to complete development, obtain regulatory approvals, and commercialize its product candidates. The company plans to expand FT819 clinical investigation outside the U.S. in 2026 and complete IND-enabling activities for FT839 in 2026. Updates on FT836 patients are expected in the second half of 2026.

Management Comments

• We believe our proprietary clonal master iPSC lines can be used to mass produce multiplexed-engineered, cellular immunotherapies which have off-the-shelf and on-demand availability, and that can be administered alone or in combination with standard-of-care therapies, to make cell therapies accessible to all.
• We believe our therapeutic approach with FT819 and its accessibility is highly differentiated and may offer a more convenient and favorable experience for patients, including outpatient treatment.
• We believe the independent assessment of multiple B cell-mediated autoimmune diseases under one Phase 1 basket study enables the most cost-effective and efficient pathway for broad clinical development.
• We believe there is a significant opportunity to combine, in the absence of conditioning chemotherapy, FT522 with CD20 or CD38 targeted antibodies to drive deeper B-cell depletion, and achieve higher rates of clinical remissions, for the treatment of autoimmune diseases.
• We believe the novel targeting strategy of FT836 coupled with its ability to be combined with standard-of-care treatment regimens, such as therapeutic monoclonal antibodies, can significantly improve patient outcomes in the treatment of solid tumors while also supporting broad patient accessibility.
• We believe there is significant opportunity to develop off-the-shelf CAR T-cell therapies that incorporate multiple therapeutic mechanisms of action and can be combined with standard-of-care treatment regimens to significantly improve patient outcomes in the treatment of many diseases.
• We believe that the use of a more tolerable treatment paradigm for cellular immunotherapies may significantly improve the patient experience, expand patient reach, and enhance our therapeutic differentiation.
• We believe we are well positioned to form partnerships with third parties seeking to develop and commercialize iPSC-derived cell therapies for the treatment of human diseases.
• We believe we have sufficient funding to operate for at least twelve months from the date of issuance of the financial statements.

Industry Context

StockSavvy.ai notes that Fate Therapeutics operates in the highly competitive and rapidly innovating biotechnology and pharmaceutical industries, particularly in immune-oncology and cell therapies. The company's focus on iPSC-derived, off-the-shelf cellular immunotherapies represents a novel approach, aiming to overcome the logistical and manufacturing complexities of autologous cell therapies. The RMAT designation for FT819 in SLE positions it as a potential leader in the emerging field of cell therapies for autoimmune diseases, an area with limited approved treatments. The ongoing FDA scrutiny of CAR T-cell therapies for T-cell malignancies highlights the regulatory challenges and safety considerations inherent in this space, which Fate Therapeutics must navigate carefully. The company's strategy to develop conditioning chemotherapy-free regimens (e.g., FT836, FT522) could be a significant differentiator in improving patient accessibility and safety compared to existing CAR T-cell therapies.

Comparison to Industry Standards

• FT819's preliminary Phase 1 data in SLE, showing rapid B-cell depletion and clinical remission, is supported by a groundbreaking academic clinical study published in Nature Medicine in September 2022, which used autologous CD19-targeted CAR T-cell therapy for SLE patients. Fate's approach aims for less intense conditioning and on-demand availability, potentially offering a more accessible alternative.
• The safety profile of FT819 in B-cell malignancies (no DLTs, ICANS, GvHD, low CRS incidence of 14%) appears favorable compared to currently approved autologous CAR T-cell therapies (e.g., Kymriah (Novartis AG), Yescarta (Kite Pharma), Breyanzi (Bristol-Myers Squibb Company), Abecma (Bristol-Myers Squibb Company), and Carvykti (Janssen Biotech)) which have shown frequent rates of adverse events including CRS and ICANS.
• FT825's novel HER2 binding domain, derived from cancer-specific monoclonal antibody H2CasMab-2, demonstrated highly selective targeting against HER2-expressing cancer cell lines versus healthy tissue in preclinical studies, differentiating it from other HER2-directed agents like trastuzumab (Herceptin).
• The development of FT836 and FT839 with Sword & Shield technology (ADR + CD58KO) aims to enable administration without intense conditioning chemotherapy, a significant advancement compared to current CAR T-cell therapies that often require such regimens.

Management Changes

Corporate Governance

Legal Proceedings

• Securities class action lawsuit (Hadian v. Fate Therapeutics, Inc. et al.) filed January 20, 2023, alleging false/misleading statements regarding the Janssen Agreement and its termination. Motions to dismiss have been granted with leave to amend, and the third amended complaint is currently under review.
• Derivative actions (Guarino v. Wolchko, et al., Horrobin v. Wolchko, et al., West v. Wolchko, et al.) filed June 2, 2023, June 12, 2024, and December 17, 2025, respectively, against board members and officers, asserting claims for breach of fiduciary duty, unjust enrichment, abuse of control, gross mismanagement, waste of corporate assets, and insider trading, arising from similar facts as the Securities Action. These actions are currently stayed pending decisions in the Securities Action.

Related Party Transactions

• Entities affiliated with Redmile Group, LLC (Redmile) hold 2,755,086 shares of Class A Convertible Preferred Stock, which are convertible into common stock subject to a beneficial ownership limitation (increased to 14.99% effective August 31, 2025).
• A fund affiliated with Redmile Group, LLC purchased pre-funded warrants to purchase 3,636,364 shares of common stock in a private placement concurrent with the March 2024 underwritten public offering.
• Directors and officers of the company are affiliated with investors who purchased convertible preferred stock and common stock in the November 2016 private placement transaction.

Stakeholder Impact

• Shareholders: Potential dilution from future equity raises, volatility in stock price due to clinical trial results and market conditions, impact from ongoing legal proceedings, and influence of principal stockholders and management.
• Patients: Potential for transformative off-the-shelf cellular immunotherapies for serious autoimmune diseases and cancers, with efforts to improve accessibility (e.g., conditioning-free regimens).
• Employees: Workforce reduction (12% in August 2025) due to corporate restructuring, but ongoing commitment to competitive compensation, benefits, and development for remaining staff.
• Collaborators (Ono Pharmaceutical): Continued joint development and potential for significant milestone payments and royalties.
• Regulatory Bodies (FDA, MHRA, EMA): Ongoing engagement for product candidate approvals, RMAT designation, and compliance with evolving cell therapy regulations.
• Creditors: Potential for increased fixed payment and interest obligations if debt financing is pursued.

Next Steps

• Continue regulatory development of FT819 in SLE, including submission of a Phase 2 registration-enabling clinical protocol in lupus nephritis.
• Investigate the potential of FT819 as a treatment for extrarenal lupus in a second trial.
• Advance FT819 to Biologics License Application (BLA) filing over the course of the next several years.
• Continue to expand FT819 clinical investigation outside of the United States in 2026.
• Complete dose level 1, escalate to dose level 2 (900 million cells), and expand treatment to Regimen D (twice-dosed FT819) in Regimen B (conditioning-free) for SLE.
• Continue enrollment in dose-expansion cohorts for FT819 in SSc, AAV, and IIM.
• Continue enrollment in the multi-center, Phase 1 study of FT825 for advanced solid tumors at the third dose level (900 million cells) as monotherapy and in combination with EGFR-targeted monoclonal antibody therapy.
• Provide an update on patients treated in the FT836 Phase 1 trial in the second half of 2026.
• Complete IND-enabling activities in 2026 to support initial clinical investigation of FT839 for cancer and autoimmune diseases.
• Evaluate opportunities for further clinical development of FT522 in autoimmune indications.
• Continue to receive committed funding under the joint development plan from Ono Pharmaceutical through June 2026.
• Seek additional funds through public or private equity or debt financings, government or other third-party funding, marketing and distribution arrangements, and other collaborations.
• Make significant investments to maintain and expand existing GMP manufacturing capabilities and facilities, establish additional GMP facilities, and conduct GMP production.

Key Dates

Recommendation

The company shows promising clinical progress with its iPSC-derived cell therapies, particularly the RMAT designation for FT819 and the initiation of conditioning-free trials for FT836. The reduced net loss and expense management are positive financial indicators. However, the company remains clinical-stage with no product revenue, continues to incur significant losses, and faces substantial future funding needs. The ongoing legal proceedings add a layer of uncertainty. While the long-term potential is high, the speculative nature of early-stage biotech, coupled with the need for further capital and resolution of legal matters, suggests a 'hold' recommendation for investors who are already invested or considering a position, awaiting further de-risking clinical data and clarity on commercialization pathways.

Keywords

Cellular Immunotherapy, iPSC, CAR T-cell, CAR NK cell, Autoimmune Disease, Systemic Lupus Erythematosus, SLE, Lupus Nephritis, Solid Tumors, Oncology, Biopharmaceutical, Clinical Stage, FDA RMAT, FT819, FT825, FT836, FT522, Ono Pharmaceutical, Gene Editing, Off-the-shelf, Biotechnology, Risk Factors, 10-K